The fifteen-month dataset represents the final analysis from the Phase 1/2 study At the Month 15 primary timepoint, SKY-0515-treated patients showed a +1.59-point difference in Composite Unified Huntington's Disease Rating Scale (cUHDRS) change from baseline versus overlap-weighted external natural history control Differences favoring SKY-0515 were statistically significant across all four cUHDRS components – Total Functional Capacity, Total Motor Score, Symbol Digit Modalities Test and Stroop W

Presentation highlights data demonstrating that the dual LSD1/HDAC6 inhibitor achieves rapid and sustained dose-responsive reductions in platelet counts in patients with essential thrombocythemia (ET), with consistent activity also observed in polycythemia vera (PV) and other myeloproliferative neoplasms (MPNs) Sept. 15, 2026 -- Jubilant Therapeutics Inc., a clinical-stage biopharmaceutical company advancing precision therapies for hematological malignancies, today announced the presentation of

Vera Therapeutics is on course to gain full approval of Trutakna (atacicept-vymj) after announcing Tuesday that the drug met all prespecified endpoints at the final efficacy analysis of the Phase III ORIGIN 3 trial in adults with primary IgA nephropathy (IgAN) at risk for disease progression. The news sent company shares up nearly 15% in premarket trading. Trutakna, designed to simultaneously block BAFF and APRIL, gained accelerated FDA approval in July to reduce proteinuria in adults with prim

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months PD-L1 High Expression Subgroup: Hazard Ratio = 0.58 Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 tr

Sept. 14, 2026 -- Sapience Therapeutics, Inc., a clinical-stage biotechnology company dedicated to developing first-in-class peptide therapeutics targeting the underlying oncogenic and immune mechanisms driving cancer and pre-cancerous disease, today announced that the U.S. Food and Drug Administration (FDA) has granted the Company an Investigational New Drug (IND) application for ST316 (IND 184073) for the treatment of familial adenomatous polyposis (FAP), a rare inherited disorder associated w

Roche’s collaborator MediLink announces phase III data for Tam-Peli showing significantly improved overall survival in Chinese patient population with relapsed small-cell lung cancer Tambotatug pelitecan (Tam-Peli) demonstrated statistically significant efficacy over topotecan in a phase III study conducted in China, reducing the risk of death by 54% and disease progression by 71%, while achieving an objective response rate of 59.1% vs 9.7%1 The novel B7-H3-targeted antibody-drug conjugate with

The ink was barely dry on the FDA approval letter for AstraZeneca’s Etcamah before the oral SERD suffered a key clinical setback. Etcamah failed to significantly improve patients’ time before tumor progression or death compared with the aromatase inhibitor anastrozole for the first-line treatment of ER-positive, HER2-negative breast cancer, AZ said Friday. The readout comes from the Serena-4 phase 3 trial, in which all patients also received Pfizer’s CDK4/6 inhibitor Ibrance. AZ noted a numeri

SBIR Phase II award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) will support IND-enabling development of Vincere's USP30 inhibitor small molecule for acute kidney injury (AKI) Vincere's approach targets mitochondrial dysfunction and impaired mitophagy, key contributors to kidney injury and impaired recovery The award expands the clinical potential of Vincere's USP30 platform beyond Parkinson's disease and advances a second therapeutic molecule toward human s

IND clearance further expands development of C-CAR168 across chronic autoimmune diseases with significant unmet medical need Sept. 14, 2026 -- AbelZeta Pharma, Inc. ("AbelZeta" or the "Company"), a global clinical-stage biopharmaceutical company focused on the discovery and development of innovative and proprietary cell-based therapeutic products, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company's Investigational New Drug (IND) application to initiate a P

Designation is driven by compelling Phase 2 clinical data in patients with complicated Staphylococcus aureus bacteremia showing AP-SA02 may offer substantial improvement over available therapies Potentially accelerating the path to market for this innovative antibacterial treatment AP-SA02 now holds Breakthrough Therapy, Fast Track and QIDP designations, providing strong regulatory validation Sept. 14, 2026 -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a lat